Literature DB >> 21531516

Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery.

Megan E Daly1, Gary Luxton, Clara Y H Choi, Iris C Gibbs, Steven D Chang, John R Adler, Scott G Soltys.   

Abstract

PURPOSE: To determine whether normal tissue complication probability (NTCP) analyses of the human spinal cord by use of the Lyman-Kutcher-Burman (LKB) model, supplemented by linear-quadratic modeling to account for the effect of fractionation, predict the risk of myelopathy from stereotactic radiosurgery (SRS). METHODS AND MATERIALS: From November 2001 to July 2008, 24 spinal hemangioblastomas in 17 patients were treated with SRS. Of the tumors, 17 received 1 fraction with a median dose of 20 Gy (range, 18-30 Gy) and 7 received 20 to 25 Gy in 2 or 3 sessions, with cord maximum doses of 22.7 Gy (range, 17.8-30.9 Gy) and 22.0 Gy (range, 20.2-26.6 Gy), respectively. By use of conventional values for α/β, volume parameter n, 50% complication probability dose TD(50), and inverse slope parameter m, a computationally simplified implementation of the LKB model was used to calculate the biologically equivalent uniform dose and NTCP for each treatment. Exploratory calculations were performed with alternate values of α/β and n.
RESULTS: In this study 1 case (4%) of myelopathy occurred. The LKB model using radiobiological parameters from Emami and the logistic model with parameters from Schultheiss overestimated complication rates, predicting 13 complications (54%) and 18 complications (75%), respectively. An increase in the volume parameter (n), to assume greater parallel organization, improved the predictive value of the models. Maximum-likelihood LKB fitting of α/β and n yielded better predictions (0.7 complications), with n = 0.023 and α/β = 17.8 Gy.
CONCLUSIONS: The spinal cord tolerance to the dosimetry of SRS is higher than predicted by the LKB model using any set of accepted parameters. Only a high α/β value in the LKB model and only a large volume effect in the logistic model with Schultheiss data could explain the low number of complications observed. This finding emphasizes that radiobiological models traditionally used to estimate spinal cord NTCP may not apply to the dosimetry of SRS. Further research with additional NTCP models is needed. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21531516     DOI: 10.1016/j.ijrobp.2011.03.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

2.  Spinal cord tolerance to reirradiation with single-fraction radiosurgery: a swine model.

Authors:  Paul M Medin; Ryan D Foster; Albert J van der Kogel; James W Sayre; William H McBride; Timothy D Solberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-22       Impact factor: 7.038

Review 3.  Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord.

Authors:  Jimm Grimm; Arjun Sahgal; Scott G Soltys; Gary Luxton; Ashish Patel; Scott Herbert; Jinyu Xue; Lijun Ma; Ellen Yorke; John R Adler; Iris C Gibbs
Journal:  Semin Radiat Oncol       Date:  2016-01-04       Impact factor: 5.934

4.  Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study.

Authors:  Gang Liu; Lewei Zhao; An Qin; Inga Grills; Rohan Deraniyagala; Craig Stevens; Sheng Zhang; Di Yan; Xiaoqiang Li; Xuanfeng Ding
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  Clinical practice of image-guided spine radiosurgery--results from an international research consortium.

Authors:  Matthias Guckenberger; Reinhart A Sweeney; John C Flickinger; Peter C Gerszten; Ronald Kersh; Jason Sheehan; Arjun Sahgal
Journal:  Radiat Oncol       Date:  2011-12-15       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.